Latest Content

GLP-1 drugs like semaglutide may curb alcohol and opioid cravings, as trials expand, combos emerge, and interaction risks surface.

Study ties higher schizophrenia rates in Black Americans to neighborhood vulnerability, spotlighting faster early-psychosis care and social supports.

Phase 2 MINDFuL data show XPro trends toward cognitive and biomarker gains in inflammation-defined mild Alzheimer disease, with no ARIA, guiding phase 3 plans.

Psychiatry leaders unpack pharmacogenetic testing hype, spotlight 4 actionable genes, and urge evidence-based use with therapeutic drug monitoring for personalized treatment.

Massive Lancet meta-analysis suggests most use of antidepressants while pregnant does not raise autism or ADHD risk after confounders, easing treatment decisions.

Key schizophrenia facts: early warning signs, brain changes, treatment limits—and how AI could reveal biomarkers for more personalized care.

Federal fast-tracks boost psychedelic research.

A new report shows private practice clinicians deliver over 113 million sessions of mental health care, making up the majority of outpatient care.

How antidepressant myths can raise suicide risk—and what evidence-based prescribing, tapering, and crisis supports really look like.

Anosognosia drives untreated schizophrenia into homelessness and jail. Here's why civil care fails and how structured treatment can decrease the number of arrests.

Large meta-analysis finds GLP-1 drugs don’t raise depression or suicidality and modestly boost quality of life and eating control in diabetes/obesity.

Review news from the last week in psychiatry.

Leading psychiatric organizations respond to federal push for deprescribing.